OIG: Rebates reduced spending growth for Part D brand-name drugs
Rebates reduced the growth in Medicare Part D spending for brand-name drugs between 2011 and 2015, but spending for brand-name drugs with rebates still grew by $2 billion over the five-year period, according to a report released last week by the Department of Health and Human Services’ Office of Inspector General. Without rebates, total Part D reimbursement for brand-name drugs would have risen 19% over the period, OIG found. In response to a congressional request, OIG examined 1,510 brand-name drugs with Part D reimbursement and rebates each year over the period.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services today issued a final rule that would increase Medicare rates by a net 2.3% in fiscal year 2027, compared with…
Headline
The Centers for Medicare & Medicaid Services July 27 released its Contract Year 2025 Part C and Part D Program Audit and Enforcement Report, outlining key…
Headline
The Centers for Medicare & Medicaid Services has released an updated FAQ on Protecting Access to Medicare Act private payer data reporting. The deadline is…
Headline
The Centers for Medicare & Medicaid Services July 16 released draft guidance for the 2028 cycle of negotiations under the Medicare Drug Price Negotiation…
Headline
The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible…
Headline
A blog by Noah Isserman, AHA director of health insurance and coverage policy, explains why a recent analysis by the Medicare Payment Advisory Commission…